Valgerdur Runarsdottir
Overview
Explore the profile of Valgerdur Runarsdottir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olafsson S, Love T, Fridriksdottir R, Tyrfingsson T, Runarsdottir V, Hansdottir I, et al.
Int J Drug Policy
. 2024 Oct;
133:104616.
PMID: 39454253
Background: Limited data exists about treatment outcomes in nationwide hepatitis C virus (HCV) elimination programs where injection drug use (IDU) is the main mode of transmission. In 2016 Iceland initiated...
2.
3.
Saunders G, Wang X, Chen F, Jang S, Liu M, Wang C, et al.
Nature
. 2022 Dec;
612(7941):720-724.
PMID: 36477530
Tobacco and alcohol use are heritable behaviours associated with 15% and 5.3% of worldwide deaths, respectively, due largely to broad increased risk for disease and injury. These substances are used...
4.
Gaddis N, Mathur R, Marks J, Zhou L, Quach B, Waldrop A, et al.
Sci Rep
. 2022 Oct;
12(1):16873.
PMID: 36207451
Opioid addiction (OA) is moderately heritable, yet only rs1799971, the A118G variant in OPRM1, has been identified as a genome-wide significant association with OA and independently replicated. We applied genomic...
5.
Johannesson J, Fridriksdottir R, Love T, Runarsdottir V, Hansdottir I, Love A, et al.
Clin Infect Dis
. 2022 Apr;
75(10):1732-1739.
PMID: 35438144
Background: The Treatment as Prevention for Hepatitis C program started in 2016 in Iceland, offering treatment with direct-acting antivirals to hepatitis C virus (HCV)-infected individuals. Reinfections through injection drug use...
6.
Olafsson S, Fridriksdottir R, Love T, Tyrfingsson T, Runarsdottir V, Hansdottir I, et al.
Lancet Gastroenterol Hepatol
. 2021 Jun;
6(8):628-637.
PMID: 34171267
Background: WHO has set targets to eliminate hepatitis C virus (HCV) infection as a global health threat by 2030 through a 65% reduction in HCV-related deaths and 80% reduction in...
7.
Johnson E, Demontis D, Thorgeirsson T, Walters R, Polimanti R, Hatoum A, et al.
Lancet Psychiatry
. 2020 Oct;
7(12):1032-1045.
PMID: 33096046
Background: Variation in liability to cannabis use disorder has a strong genetic component (estimated twin and family heritability about 50-70%) and is associated with negative outcomes, including increased risk of...
8.
Gedeon C, Sandell M, Birkemose I, Kakko J, Runarsdottir V, Simojoki K, et al.
Nordisk Alkohol Nark
. 2020 Sep;
36(3):286-298.
PMID: 32934565
Aims: Outcomes in opioid use disorder (OUD) in Nordic countries have improved with integrated treatment and harm-reduction programmes. Approaches and the standard of care are different across the region. Evidence...
9.
Demontis D, Rajagopal V, Thorgeirsson T, Als T, Grove J, Leppala K, et al.
Nat Neurosci
. 2019 Jun;
22(7):1066-1074.
PMID: 31209380
Cannabis is the most frequently used illicit psychoactive substance worldwide; around one in ten users become dependent. The risk for cannabis use disorder (CUD) has a strong genetic component, with...
10.
Liu M, Jiang Y, Wedow R, Li Y, Brazel D, Chen F, et al.
Nat Genet
. 2019 Jan;
51(2):237-244.
PMID: 30643251
Tobacco and alcohol use are leading causes of mortality that influence risk for many complex diseases and disorders. They are heritable and etiologically related behaviors that have been resistant to...